News | July 03, 2025
WuXi XDC announces mechanical completion of Singapore site
The site, spanning approximately 25,000 square meters, is expected to commence operations by the end of 2025
The site, spanning approximately 25,000 square meters, is expected to commence operations by the end of 2025
The trial targets MCAS/MCAD, an under-recognized, debilitating condition with an unknown cause and no cure
PAT stood at Rs. 88 crore for Q4 FY25 as compared to Rs. 56 crore in Q4FY24, an increase of 57%
The foray into this new segment will help Vimta to enter into the growing CDMO business of biologics and peptides
The partnership provides Sai Life Sciences with a greenhouse gas emissions reduction of up to 90% for its international logistics needs by using SAF
Asahi Kasei Life Science covers a broad range of bioprocess products and services
The Peptide Research Center is designed to support innovator pharma and biotech companies with specialized services across peptide synthesis, discovery, and advanced modalities, including complex conjugates
Being a premium partner for pharmaceutical companies by contributing to safety and productivity of pharmaceutical manufacture
Overall investment in the US facility is estimated around US$50 million
WuXi XDC's fully integrated ADC discovery service platform will significantly boost the speed and efficiency of LigaChem's ADC development programs
Subscribe To Our Newsletter & Stay Updated
